IRWD - Ironwood Pharmaceuticals Non-GAAP EPS of $0.28 beats by $0.01 revenue of $108.64M misses by $1.76M reaffirms FY guidance
- Ironwood Pharmaceuticals press release ( NASDAQ: IRWD ): Q3 Non-GAAP EPS of $0.28 beats by $0.01 .
- Revenue of $108.64M (+4.7% Y/Y) misses by $1.76M .
- Reaffirms FY22 Guidance: In 2022, Ironwood continues to expect: U.S. LINZESS Net Sales Growth Low single digits %; total revenue of $420 to $430 million vs. consensus of $422.67M and Adjusted EBITDA of >$250 million.
For further details see:
Ironwood Pharmaceuticals Non-GAAP EPS of $0.28 beats by $0.01, revenue of $108.64M misses by $1.76M, reaffirms FY guidance